QQQ   444.71 (-0.03%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
QQQ   444.71 (-0.03%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
QQQ   444.71 (-0.03%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
QQQ   444.71 (-0.03%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
NASDAQ:INZY

Inozyme Pharma (INZY) Stock Price, News & Analysis

$7.39
0.00 (0.00%)
(As of 12:03 PM ET)
Today's Range
$7.28
$7.61
50-Day Range
$4.21
$7.39
52-Week Range
$2.69
$7.61
Volume
364,895 shs
Average Volume
526,996 shs
Market Capitalization
$456.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

Inozyme Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
138.1% Upside
$18.00 Price Target
Short Interest
Bearish
5.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Inozyme Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.48) to ($1.58) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.98 out of 5 stars

Medical Sector

804th out of 939 stocks

Pharmaceutical Preparations Industry

373rd out of 434 stocks

INZY stock logo

About Inozyme Pharma Stock (NASDAQ:INZY)

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

INZY Stock Price History

INZY Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Inozyme Pharma: Q4 Earnings Insights
Inozyme Pharma: Q4 Earnings Insights
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
INZY May 2024 5.000 put
Bakker Juliet Tammenoms's Net Worth
Inozyme Pharma, Inc. (INZY)
Inozyme Pharma Inc Ordinary Shares INZY
TD Cowen Reaffirms Their Buy Rating on Inozyme Pharma (INZY)
See More Headlines
Receive INZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/12/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INZY
Fax
N/A
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$23.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+138.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-71,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.27 per share

Miscellaneous

Free Float
54,433,000
Market Cap
$466.98 million
Optionable
Optionable
Beta
1.34
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Douglas A. Treco Ph.D. (Age 66)
    CEO & Chairman
    Comp: $77k
  • Mr. Axel Bolte M.B.A. (Age 52)
    M.Sc., Co-Founder, Senior Advisor & Director
    Comp: $1.03M
  • Mr. Sanjay S. Subramanian M.B.A. (Age 47)
    M.S., Senior VP, CFO & Principal Accounting Officer
    Comp: $726.3k
  • Dr. Demetrios Braddock M.D.
    Ph.D., Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer
  • Dr. Matthew Winton Ph.D. (Age 46)
    Senior VP & COO
  • Dr. Soojin Kim Ph.D.
    Senior VP & Chief Technical Operations Officer
  • Dr. David Thompson M.A.
    M.S., Ph.D., Senior VP, Chief Scientific Officer & Chief Development Officer
  • Mr. Stefan Riley
    Director of Investor Relations
  • Ms. Gayle Gironda
    Senior VP & Chief People Officer
  • Dr. Yves Sabbagh Ph.D.
    Chairman of Scientific Advisory Board & Senior VP

INZY Stock Analysis - Frequently Asked Questions

Should I buy or sell Inozyme Pharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inozyme Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INZY shares.
View INZY analyst ratings
or view top-rated stocks.

What is Inozyme Pharma's stock price target for 2024?

3 Wall Street research analysts have issued 1-year target prices for Inozyme Pharma's shares. Their INZY share price targets range from $15.00 to $23.00. On average, they anticipate the company's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 138.1% from the stock's current price.
View analysts price targets for INZY
or view top-rated stocks among Wall Street analysts.

How have INZY shares performed in 2024?

Inozyme Pharma's stock was trading at $4.26 at the beginning of the year. Since then, INZY stock has increased by 77.5% and is now trading at $7.56.
View the best growth stocks for 2024 here
.

When is Inozyme Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our INZY earnings forecast
.

How were Inozyme Pharma's earnings last quarter?

Inozyme Pharma, Inc. (NASDAQ:INZY) posted its earnings results on Tuesday, March, 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.04.

What other stocks do shareholders of Inozyme Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inozyme Pharma investors own include Procter & Gamble (PG), RTX (RTX), Cisco Systems (CSCO), CSX (CSX), CVS Health (CVS), Home Depot (HD), Resideo Technologies (REZI), Thermo Fisher Scientific (TMO) and Abbott Laboratories (ABT).

When did Inozyme Pharma IPO?

Inozyme Pharma (INZY) raised $75 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Inozyme Pharma's major shareholders?

Inozyme Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Eventide Asset Management LLC (5.15%), Vanguard Group Inc. (3.86%), Vanguard Group Inc. (3.86%), Affinity Asset Advisors LLC (3.05%), Sphera Funds Management LTD. (2.53%) and Blue Owl Capital Holdings LP (2.06%). Insiders that own company stock include Axel Bolte, Henric Bjorn Bjarke, Longitude Capital Partners Iii, Pivotal Bioventure Partners Fu and Robert Lorne Hopfner.
View institutional ownership trends
.

How do I buy shares of Inozyme Pharma?

Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INZY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners